With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Meanwhile, the latest consensus estimate predicts the revenue to be $2.68 billion, indicating a 7.83% increase compared to the same quarter of the previous year. VRTX's full-year Zacks Consensus ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

We can also see that VRTX currently has a PEG ratio of 2.08. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate.

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading ... Revenues are expected to be $2.77 billion, up 10.2% from the year-ago quarter. While earnings and revenue growth ...